Antifungal compounds: controversies, queries and conclusions.
A new session in this Congress was the development of a discussion panel regarding controversies and queries about the main topics of treatment and prophylaxis of severe systemic mycoses. Experts presenting each side of three controversial areas provided an interchange of ideas and clarified those areas where there remain substantial disagreements. Some common recommendations have been made, and some differences persist. The contents of this session are compiled in this paper. Due to the limitations of space, this paper presents the most relevant parts of each presentation. The large and up-to-date list of references should be useful to gain a better understanding of these subjects.
Graybill
J R
JR
University of Texas Health Science Center, San Antonio 78284, USA. jrgraybill@aol.com
Tollemar
J
J
Torres-Rodríguez
J M
JM
Walsh
T J
TJ
Roilides
E
E
Farmaki
E
E
D000666:Amphotericin B / Q000627:therapeutic use*; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D018890:Chemoprevention; D004338:Drug Combinations; D006801:Humans; D051379:Mice; D009181:Mycoses / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control*; D010713:Phosphatidylcholines / Q000627:therapeutic use*; D010715:Phosphatidylglycerols / Q000627:therapeutic use*
D000935:Antifungal Agents; D004338:Drug Combinations; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; C068538:liposomal amphotericin B; D000666:Amphotericin B